Outlook Therapeutics disclosed a new share offering in a July 17, 2026, regulatory filing. Selling stockholders plan to offer up to 17.26 million common shares. The company will receive no proceeds from this secondary sale. This volume of shares may create downward pressure on the stock price.
Stockholders approved a major capital structure overhaul during a special meeting on July 16, 2026. The company increased its authorized common stock from 260 million to 600 million shares. Investors also authorized a potential reverse stock split to provide future financing flexibility. These structural changes introduce the potential for significant shareholder dilution.